Jointown Pharmaceutical Group Co Ltd (600998) — Capital Reinvestment Ratio

Latest as of September 2025: 0.53x

Jointown Pharmaceutical Group Co Ltd (600998) has a Capital Reinvestment Ratio of 0.53x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥528.22 Million) in capital expenditures (CN¥281.66 Million). Check tangible net worth ratio of Jointown Pharmaceutical Group Co Ltd to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.53x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥528.22 Million
CNY

Capital Expenditures

CN¥281.66 Million
CNY

Data as of

Sep 2025
Most recent filing

Jointown Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (2007–2024)

This chart tracks Jointown Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see Jointown Pharmaceutical Group Co Ltd operating cash flow efficiency.

Annual Capital Reinvestment Ratio for Jointown Pharmaceutical Group Co Ltd (2007–2024)

Year-by-year Capital Reinvestment Ratio for Jointown Pharmaceutical Group Co Ltd from 2007 to 2024. See Jointown Pharmaceutical Group Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 0.32x CN¥3.08 Billion CN¥975.42 Million ▲ +44.3%
2023 0.22x CN¥4.78 Billion CN¥1.05 Billion ▼ -29.7%
2022 0.31x CN¥3.99 Billion CN¥1.24 Billion ▼ -22.2%
2021 0.40x CN¥3.46 Billion CN¥1.39 Billion ▼ -5.3%
2020 0.42x CN¥3.44 Billion CN¥1.46 Billion ▼ -1.8%
2019 0.43x CN¥2.77 Billion CN¥1.19 Billion ▼ -71.0%
2018 1.49x CN¥1.22 Billion CN¥1.81 Billion ▼ -44.3%
2016 2.67x CN¥431.26 Million CN¥1.15 Billion ▲ +15.3%
2015 2.31x CN¥435.96 Million CN¥1.01 Billion ▼ -47.8%
2013 4.43x CN¥138.47 Million CN¥613.81 Million ▲ +596.5%
2008 0.64x CN¥494.75 Million CN¥314.90 Million ▼ -85.7%
2007 4.44x CN¥65.95 Million CN¥293.03 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow